Newsroom | 72728 results

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...

سان كارلوس، كاليفورنيا و ريدوود سيتي، كاليفورنيا--(BUSINESS WIRE)--أعلنت BeOne Medicines Ltd. (المدرجة في بورصة ناسداك بالرمز: ONC؛ وبورصة هونج كونج: 06160؛ وبورصة شنغهاي: 688235)، إحدى الشركات العالمية المتخصصة في علم الأورام، وRevolution Medicines, Inc. (المدرجة في بورصة ناسداك بالرمز: RVMD)، وهي شركة متخصصة في تطوير علاجات موجهة للمرضى المصابين بالسرطانات المعتمدة على RAS وفي مرحلة متقدمة من التطوير السريري، عن إبرام تعاون متعدد الأوجه يتضمن محورين رئيسيين: تعاونًا سريريًا لتقييم تركيبات دوائ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2026. Management will host a conference call Tuesday, August 11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 202...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026. “Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care. We’re proving, quarter after quarter, that helping people feel great and delivering strong...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--The Beachbody Company, Inc. (NASDAQ: BODi) (“BODi” or the “Company”), the proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out, today announced financial results for its second quarter ended June 30, 2026. “Q2 marks our fourth consecutive quarter of net income and operating income, further validating the strength of our transformed business model,” said Carl Dai...

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Sept. 9, 2026, to shareholders of record on Aug. 28, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scien...

米カリフォルニア州サンカルロスおよびカリフォルニア州レッドウッドシティ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 腫瘍分野でグローバルに展開するBeOne Medicines（ナスダック：ONC、香港証券取引所：06160、上海証券取引所：688235、「BeOne」）とRAS依存性癌患者向けに後期臨床段階で腫瘍標的療法を開発するRevolution Medicines（ナスダック：RVMD）は、多岐にわたる提携を発表しました。この提携には、BeOneの特定の臨床段階にある腫瘍関連の薬剤資産と、Revolution Medicinesの4種類の臨床段階にあるRAS（ON）阻害剤との併用療法を評価する臨床提携、および特定のアジア市場におけるRevolution Medicinesの薬剤資産の独占的な開発・商業化権をBeOneに付与する地域別権利契約が含まれます。 この臨床提携は、RAS依存性癌患者を対象とした標的併用療法のアプローチの可能性を模索 臨床提携の一環として開発が検討される併用療法の候補には、BeOneの特定の薬剤候補と、Revolution Medici...

SAN CARLOS, Califórnia e REDWOOD CITY, Califórnia--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa multinacional de oncologia, e Revolution Medicines, Inc. (Nasdaq: RVMD), Uma empresa de oncologia clínica em estágio avançado que desenvolve terapias direcionadas a pacientes com tipos de câncer que dependem de RAS anunciou hoje uma cooperação de múltiplas etapas, incluindo: uma cooperação clínica para avaliar combinações de medicamentos que incorporem at...

SAN CARLOS, California, y REDWOOD CITY, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa global especializada en oncología, y Revolution Medicines, Inc. (Nasdaq: RVMD), una empresa biofarmacéutica en fase clínica avanzada que desarrolla terapias dirigidas para pacientes con cánceres dependientes de RAS, anunciaron hoy una colaboración que comprende dos acuerdos. El primero es una colaboración clínica para evaluar combinaciones de determinado...

MEMPHIS, Tenn.--(BUSINESS WIRE)--As 70 of the world's best golfers descend on Memphis for the 2026 FedEx St. Jude Championship, patients from St. Jude Children’s Research Hospital® will once again be at the heart of tournament week, showcasing the powerful impact of the supporters, partners and communities helping advance its lifesaving mission. The 2026 FedEx St. Jude Championship, Aug. 13-16 at TPC Southwind, brings together the top players in the FedExCup standings while continuing a decades...